Reply to Araki et al

Affiliations

¹ Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: alipton@hmc.psu.edu.
² Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
³ University of Arizona, Arizona Cancer Center, Tucson, AZ, USA.
⁴ Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA, USA.
⁵ Amgen Inc., Thousand Oaks, CA, USA.

Comment

Allan Lipton et al. Eur J Cancer. 2013 Jun.

. 2013 Jun;49(9):2266-8.

doi: 10.1016/j.ejca.2013.02.037. Epub 2013 Apr 8.

¹ Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: alipton@hmc.psu.edu.
² Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
³ University of Arizona, Arizona Cancer Center, Tucson, AZ, USA.
⁴ Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA, USA.
⁵ Amgen Inc., Thousand Oaks, CA, USA.

No abstract available

Comment on

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Lipton A, et al. Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10. Eur J Cancer. 2012. PMID: 22975218
Re: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of three pivotal, randomised, phase 3 trials.
Araki K, Ito Y, Takahashi S. Araki K, et al. Eur J Cancer. 2013 Jun;49(9):2264-5. doi: 10.1016/j.ejca.2013.02.036. Epub 2013 Mar 27. Eur J Cancer. 2013. PMID: 23541567 No abstract available.